Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain

@article{Minkowitz2015LongtermSO,
  title={Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain},
  author={Harold S. Minkowitz and Janet K. Bull and R. Charles Brownlow and Neha Jagdish Parikh and Richard L. Rauck},
  journal={Supportive Care in Cancer},
  year={2015},
  volume={24},
  pages={2669-2675}
}
The current study assessed the long-term safety of fentanyl sublingual spray for managing breakthrough cancer pain (BTCP). This open-label, multicenter study enrolled both de novo and rollover patients who completed a double-blind, efficacy trial. Eligible patients were ≥18 years of age and experiencing pain that was being managed with an around-the-clock opioid yet were experiencing ≤4 BTCP episodes daily and were opioid-tolerant (i.e., receiving ≥60 mg/day oral morphine or an equivalent dose… CONTINUE READING
BETA
1
Twitter Mention

References

Publications referenced by this paper.
SHOWING 1-10 OF 18 REFERENCES

Fentanyl for breakthrough pain: a systematic review.

  • Expert review of neurotherapeutics
  • 2011
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

The role of fentanyl in cancer-related pain.

  • Journal of palliative medicine
  • 2009
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.

  • Journal of pain and symptom management
  • 2001
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Breakthrough cancer pain (BTcP): from definitions to patient burden

G Zeppetella
  • Eur J Palliat Care
  • 2010
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…